{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:12:13Z","timestamp":1761919933127,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ecl.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T01:00:37Z","timestamp":1416963637000},"page":"949-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Lipoprotein(a)"],"prefix":"10.1016","volume":"43","author":[{"given":"Marlys L.","family":"Koschinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2014.08.002_bib1","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","article-title":"Physicochemical properties of apolipoprotein(a) and lipoprotein(a\u2212) derived from the dissociation of human plasma lipoprotein (a)","volume":"261","author":"Fless","year":"1986","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib2","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ecl.2014.08.002_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"van der Hoek","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ecl.2014.08.002_bib5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/hmg\/2.7.933","article-title":"Molecular definition of the extreme size polymorphism in apolipoprotein(a)","volume":"2","author":"Lackner","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ecl.2014.08.002_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/clinchem\/40.4.574","article-title":"Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00041433-199904000-00007","article-title":"Genetic architecture and evolution of the lipoprotein(a) trait","volume":"10","author":"Utermann","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ecl.2014.08.002_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib10","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1074\/jbc.272.8.5048","article-title":"Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum","volume":"272","author":"White","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib11","series-title":"Lipoprotein(a)","first-page":"211","article-title":"Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels","author":"Brewer","year":"1990"},{"key":"10.1016\/j.ecl.2014.08.002_bib12","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2014.08.002_bib13","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib14","doi-asserted-by":"crossref","first-page":"e1002260","DOI":"10.1371\/journal.pgen.1002260","article-title":"Large-scale gene-centric analysis identifies novel variants for coronary artery disease","volume":"7","author":"IBC 50K CAD Consortium","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ecl.2014.08.002_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2014.08.002_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0b013e32835111d8","article-title":"Lipoprotein(a): more interesting than ever after 50 years","volume":"23","author":"Dub\u00e9","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ecl.2014.08.002_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCGENETICS.109.907642","article-title":"Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians","volume":"3","author":"Lanktree","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ecl.2014.08.002_bib18","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A\u00a0polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2014.08.002_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1476-511X-12-127","article-title":"Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention","volume":"12","author":"Li","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ecl.2014.08.002_bib20","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2014.08.002_bib21","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-2275(20)37595-7","article-title":"Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2","volume":"37","author":"Tam","year":"1996","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2014.08.002_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0021-9150(02)00072-2","article-title":"Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk","volume":"164","author":"Gonbert","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2014.08.002_bib25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/heart.89.8.893","article-title":"Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia","volume":"89","author":"van Wissen","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.ecl.2014.08.002_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2011.09.060","article-title":"Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials","volume":"154","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib28","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.M038877","article-title":"Scavenger receptor-BI is a receptor for lipoprotein(a)","volume":"54","author":"Yang","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11883-013-0360-6","article-title":"Update on lipoprotein(a) as a cardiovascular risk factor and mediator","volume":"15","author":"Boffa","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ecl.2014.08.002_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1749-6632.2001.tb03514.x","article-title":"Inhibition of fibrinolysis by lipoprotein(a)","volume":"936","author":"Angl\u00e9s-Cano","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ecl.2014.08.002_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.ecl.2014.08.002_bib33","doi-asserted-by":"crossref","first-page":"30503","DOI":"10.1074\/jbc.M802648200","article-title":"Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway","volume":"283","author":"Cho","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1091\/mbc.e12-08-0637","article-title":"Apolipoprotein(a) stimulates nuclear translocation of \u03b2-catenin: a novel pathogenic mechanism for lipoprotein(a)","volume":"24","author":"Cho","year":"2013","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ecl.2014.08.002_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib37","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A\u00a0novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib38","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib39","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI119671","article-title":"Lipoprotein(a) vascular accumulation in mice. In\u00a0vivo analysis of the role of lysine binding sites using recombinant adenovirus","volume":"100","author":"Hughes","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2014.08.002_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib41","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M036343","article-title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma","volume":"54","author":"Wiesner","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib43","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2014.08.002_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib47","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2014.08.002_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"Danik","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ecl.2014.08.002_bib49","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib50","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","article-title":"Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform","volume":"130","author":"Undas","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib51","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/clc.21988","article-title":"Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention","volume":"35","author":"Kardys","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejim.2012.08.014","article-title":"Lipoprotein (a) is independently correlated with coronary artery calcification","volume":"24","author":"Greif","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.numecd.2013.02.009","article-title":"Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort","volume":"23","author":"Sung","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ecl.2014.08.002_bib55","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12265-011-9273-3","article-title":"Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of noninvasive imaging for evaluation of an emerging risk factor","volume":"4","author":"Sharma","year":"2011","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.atherosclerosis.2013.04.015","article-title":"Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf recall study","volume":"229","author":"Erbel","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2014.08.002_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2010.02.021","article-title":"Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women","volume":"150","author":"Qasim","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacl.2010.07.002","article-title":"Management of Lp(a)","volume":"4","author":"Brown","year":"2010","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ecl.2014.08.002_bib59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/joim.12187","article-title":"Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease","volume":"276","author":"Hopewell","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib60","first-page":"151","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib62","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib63","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2014.08.002_bib64","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.jacc.2010.09.001","article-title":"American College of Cardiology Foundation; American Heart Association. 2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults","volume":"56","author":"Greenland","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib65","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","article-title":"When should we measure lipoprotein (a)?","volume":"34","author":"Kostner","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2014.08.002_bib66","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib67","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/clinchem\/45.7.1039","article-title":"Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham heart study","volume":"45","author":"Seman","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2014.08.002_bib68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacl.2012.01.004","article-title":"Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups","volume":"6","author":"Konerman","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ecl.2014.08.002_bib69","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib70","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), cardiovascular disease, and contemporary management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ecl.2014.08.002_bib71","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy","volume":"51","author":"Nicholls","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ecl.2014.08.002_bib72","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib73","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2014.08.002_bib74","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib75","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ecl.2014.08.002_bib77","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib78","first-page":"118","article-title":"Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises","volume":"71","author":"Besseling","year":"2013","journal-title":"Neth J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib79","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2014.08.002_bib80","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib81","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2014.08.002_bib82","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib83","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2014.08.002_bib84","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib85","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib86","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2014.08.002_bib87","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2014.08.002_bib88","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2014.08.002_bib89","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib90","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2014.08.002_bib92","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ecl.2014.08.002_bib93","doi-asserted-by":"crossref","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852914000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852914000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:20Z","timestamp":1760175500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852914000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0889852914000711"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2014.08.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a)","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}